Latest stories on VRDN
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
StockTitan50 · neutralgeneral
Viridian Intersects Sulphides Throughout 3 km of Step-Out Drilling at Kraken Main
GlobeNewswire59 · neutralproduct/pr
Viridian Therapeutics price target raised to $38 from $36 at RBC Capital
The Fly63 · neutralanalyst
Viridian Therapeutics: Two Products, One Commercial Buildout
Seeking Alpha56 · neutralproduct/pr
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
StockTitan56 · neutralgeneral
Viridian Therapeutics Price Target Raised To 39 From 38 At Truist
The Fly61 · neutralanalyst
Viridian Therapeutics Price Target Raised To 36 From 35 At Rbc Capital
The Fly61 · neutralanalyst
Viridian Therapeutics, Inc.\DE (VRDN) files 8-K
SEC 8-K50 · neutralgeneral
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
StockTitan56 · neutralearnings
Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)
Yahoo Top68 · bullishanalyst
Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone
Yahoo Finance68 · bullishanalyst
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease - Slideshow
Seeking Alpha73 · bullishproduct/pr
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval
Seeking Alpha78 · bullishproduct/pr
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript
Seeking Alpha73 · bullishproduct/pr
Biggest stock movers Monday: GME, BTI, and more
Seeking Alpha54 · neutralgeneral
Viridian launches first commercial product as U.S. approves thyroid eye disease therapy
Seeking Alpha67 · bullishproduct/pr
Viridian Therapeutics Says FDA Approves Lumvoa to Treat Thyroid Eye Disease
Morningstar76 · bullishproduct/pr
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval
Stocktwits News73 · bullishproduct/pr
Viridian Therapeutics, Inc.\DE (VRDN) files 8-K
SEC 8-K50 · neutralgeneral
Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates
Seeking Alpha67 · bullishanalyst
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha56 · neutralgeneral
Viridian Therapeutics Fully Repays Loan, Ends Agreement
TipRanks62 · neutralgeneral
Viridian Therapeutics to Participate in Upcoming June Investor Conferences | VRDN Stock News
StockTitan56 · neutralgeneral